Prosecution Insights
Last updated: April 19, 2026

Examiner: BALLARD, KIMBERLY

Tech Center 1600 • Art Units: 1649 1675

This examiner grants 54% of resolved cases

Performance Statistics

53.7%
Allow Rate
-6.3% vs TC avg
664
Total Applications
+48.8%
Interview Lift
1227
Avg Prosecution Days
Based on 639 resolved cases, 2023–2026

Rejection Statute Breakdown

7.3%
§101 Eligibility
23.4%
§102 Novelty
22.8%
§103 Obviousness
26.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19346638 STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF Non-Final OA Merck Sharp & Dohme LLC
17623192 METHODS AND COMPOSITIONS FOR TREATING ALZHEIMER'S DISEASE Final Rejection The Regents of the University of California
16755198 A Cell-Based Seeding Assay for Huntingtin Aggregation Final Rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17568619 BK CHANNEL-MODULATING PEPTIDES AND THEIR USE Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17783505 CD122 WITH ALTERED ICD STAT SIGNALING Non-Final OA Synthekine, Inc.
17184758 PREVENTING AND TREATING AMYLOID- BETA DEPOSITION BY STIMULATION OF INNATE IMMUNITY Non-Final OA NEW YORK UNIVERSITY
17535059 COMPOUNDS AND METHODS TARGETING HUMAN TAU Non-Final OA Eli Lilly and Company
17211163 COMBINATION THERAPY Non-Final OA Eli Lilly and Company
17322482 RGMa BINDING PROTEIN AND USE THEREOF Non-Final OA NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
17459835 ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF Non-Final OA Alector LLC
17182095 MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN AND USES THEREOF Non-Final OA ABBVIE DEUTSCHLAND GMBH & CO KG
17031349 ANTI-CLEVER-1 AGENTS FOR CONTROLLING LYSOSOMAL VATPASE PROTON PUMPS TO INCREASE LYSOSOMAL PH-VALUE AND THE CROSS-PRESENTATION OF DIGESTED MATTER Non-Final OA Faron Pharmaceuticals Oy
17461862 METHODS AND COMPOSITIONS COMPRISING TAU OLIGOMERS Non-Final OA OLIGOMERIX, INC.
17679723 AMYLOID CONJUGATE AND USES AND METHODS THEREOF Final Rejection ARACLON BIOTECH, S.L.
16985387 METHODS AND REAGENTS FOR IMPROVED DETECTION OF AMYLOID BETA PEPTIDES Final Rejection ARACLON BIOTECH, S.L.
17634688 ENGINEERED INTERLEUKIN-2 RECEPTOR BETA AGONISTS Non-Final OA Elpis Biopharmaceuticals
17535029 TEST KITS, DEVICES AND METHODS FOR DETECTING INFECTION Non-Final OA Maxim Biomedical, Inc.
17378897 METHOD FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS Non-Final OA Citryll B.V.
17253569 ANTIBODY MOLECULES TO COMPLEMENT COMPONENT 5 AND USES THEREOF Non-Final OA Atarga, LLC
16619317 COMPOSITIONS AND METHODS FOR INHIBITING AMYLOID ACCUMLATION AND TAU AGGREGATION Non-Final OA OHIO STATE UNIVERSITY
16282943 HIGH SENSITIVITY IMMUNOASSAYS AND KITS FOR THE DETERMINATION OF PEPTIDES AND PROTEINS OF BIOLOGICAL INTEREST Non-Final OA Araclon Biotech

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month